A multicentre retrospective, spanish early access program study of electinib after crizotinib failure in patients with advanced ALK positive non-small cell lung cancer
Latest Information Update: 15 Sep 2022
At a glance
- Drugs Alectinib (Primary)
- Indications Adenocarcinoma; Brain metastases; Non-small cell lung cancer
- Focus Adverse reactions; Expanded access; Therapeutic Use
Most Recent Events
- 15 Sep 2022 New trial record
- 09 Aug 2022 Results presented at the 2022 World Conference on Lung Cancer